Patents by Inventor Zhaobing Xu

Zhaobing Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINE RING COMPOUND
    Publication number: 20230303564
    Abstract: A pyrimidine ring compound represented by formula (III), or a pharmaceutically acceptable salt thereof, and an application thereof in preparation of a medication for treating related diseases.
    Type: Application
    Filed: August 17, 2021
    Publication date: September 28, 2023
    Inventors: Zhaobing XU, Wen JIANG, Lihong HU, Charles Z. DING, Guoping HU, Jian LI, Shuhui CHEN, Ping CHEN, Xiaobing YAN, Yingchun LIU
  • Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor
    Patent number: 11655248
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: May 23, 2023
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Zhaobing Xu, Hailong Yang, Shiqi Han, Guoping Hu, Lihong Hu, Charles Z. Ding, Jian Li, Shuhui Chen
  • Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
    Patent number: 11453667
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: September 27, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Zhaobing Xu, Hailong Yang, Shiqi Han, Guoping Hu, Lihong Hu, Charles Z. Ding, Jian Li, Shuhui Chen
  • AZAINDOLE PYRAZOLE COMPOUNDS AS CDK9 INHIBITORS
    Publication number: 20220267321
    Abstract: The present invention discloses new azaindole pyrazole compounds as CDK9 inhibitors, in particular, compounds as represented by formula (I), pharmaceutically acceptable salts and isomers thereof, and the use of compounds represented by formula (I), pharmaceutically acceptable salts and isomers thereof, and the pharmaceutical composition containing them in the preparation of cancer drugs.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 25, 2022
    Inventors: Yingchun LIU, Zhaobing XU, Lihong HU, Charles Z. Z. DING, Wen JIANG, Jian LI, Shuhui CHEN
  • SMAC mimetics used as IAP inhibitors and use thereof
    Patent number: 11358950
    Abstract: Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 14, 2022
    Assignee: CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yingchun Liu, Zhaobing Xu, Lihong Hu, Charles Z. Ding, Xingxun Zhu, Guoping Hu, Jian Li, Shuhui Chen
  • CRYSTALLIZATION OF SMAC MIMIC USED AS IAP INHIBITOR AND PREPARATION METHOD THEREOF
    Publication number: 20220177453
    Abstract: Provided are a crystallization of an SMAC mimic used as an IAP inhibitor and a preparation method thereof; also comprised is the use of said crystallization in the preparation of a drug for treating cancer benefiting from cIAP1 inhibition. The compound of formula (I) has high crystallization stability and low hygroscopicity, and has advantages in terms of physical properties, safety, and metabolic stability, and has high drug value.
    Type: Application
    Filed: May 9, 2020
    Publication date: June 9, 2022
    Inventors: Yingchun Liu, Zhaobing Xu, Lihong Hu, Charles Z. Ding, Xingxun Zhu, Shuhui Chen
  • COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20220175917
    Abstract: The present invention relates to a combination of a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof which are used as an IAP inhibitor, and an immune checkpoint inhibitor; and use of the combination in the preparation of a cancer treatment drug.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 9, 2022
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yingchun LIU, Zhaobing XU, Shuhua HAN, Lihong HU, Charles Z. DING, Yuanfeng XIA, Haijun TONG, Lihua HE, Xin TIAN
  • PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR
    Publication number: 20210371411
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 18, 2019
    Publication date: December 2, 2021
    Inventors: Yaxian CAI, Zhaobing XU, Hailong YANG, Shiqi HAN, Guoping HU, Lihong HU, Charles Z. DING, Jian LI, Shuhui CHEN
  • SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF
    Publication number: 20210371400
    Abstract: Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.
    Type: Application
    Filed: November 13, 2018
    Publication date: December 2, 2021
    Inventors: Yingchun Liu, Zhaobing Xu, Lihong Hu, Charles Z. Ding, Xingxun Zhu, Guoping Hu, Jian Li, Shuhui Chen
  • Pyridone-Pyrimidine Derivative Acting As KRASG12C Mutein Inhibitor
    Publication number: 20210147418
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Inventors: Yaxian CAI, Zhaobing XU, Hailong YANG, Shiqi HAN, Guoping HU, Lihong HU, Charles Z. DING, Jian LI, Shuhui CHEN
  • 1,6-naphthyridine derivatives as CDK4/6 inhibitor
    Patent number: 10676474
    Abstract: Disclosed is a series of compounds acting as CDK4/6 inhibitors. Specifically disclosed are compounds as represented by formula (I), pharmaceutically acceptable salts or isomers thereof, pharmaceutical compositions containing same, and the use thereof in the preparation of drugs for treating cancers.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 9, 2020
    Assignees: CSTONE PHARMACEUTICALS, MEDSHINE DISCOVERY INC.
    Inventors: Zhaobing Xu, Lihong Hu, Charles Z. Ding, Shuhui Chen
  • Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
    Patent number: 10626107
    Abstract: A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 21, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Charles Z. Ding, Shuhui Chen, Lihong Hu, Zhaobing Xu, Yingchun Liu, Bingjie Ren, Weidong Li, Zongbin Li, Rui Zhao, Xiquan Zhang
  • CDK4/6 INHIBITOR
    Publication number: 20190315745
    Abstract: Disclosed is a series of compounds acting as CDK4/6 inhibitors. Specifically disclosed are compounds as represented by formula (I), pharmaceutically acceptable salts or isomers thereof, pharmaceutical compositions containing same, and the use thereof in the preparation of drugs for treating cancers.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 17, 2019
    Inventors: Zhaobing XU, Lihong HU, Charles Z. DING, Shuhui CHEN
  • CRYSTAL FORM, SALT TYPE OF SUBSTITUTED 2-HYDRO-PYRAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR
    Publication number: 20190194168
    Abstract: A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like.
    Type: Application
    Filed: September 8, 2017
    Publication date: June 27, 2019
    Inventors: Charles Z. Ding, Shuhui Chen, Lihong Hu, Zhaobing Xu, Yingchun Liu, Bingjie Ren, Weidong Li, Zongbin Li, Rui Zhao, Xiquan Zhang
  • Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
    Patent number: 9969719
    Abstract: Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 15, 2018
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Zhaobing Xu, Yingchun Liu, Ruibin Lin, Fei Wang, Jian Li
  • SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG
    Publication number: 20180072707
    Abstract: Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.
    Type: Application
    Filed: March 10, 2016
    Publication date: March 15, 2018
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Zhaobing Xu, Yingchun Liu, Ruibin Lin, Fei Wang, Jian Li